Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists had similar rates of other adverse events, including bone fracture, acute kidney injury, serious urinary tract infection, venous thromboembolism, and
Compared to young adults without diabetes, those with diabetes were more likely to have obesity, elevated lipids, or hypertension and were less likely to report being physically active or consuming a healthy diet.
Age, sex, body mass index, peripheral sensory neuropathy, and estimated glomerular filtration rate were the included variables.
The results highlight the potential benefit of targeting individuals with an elevated one-hour blood glucose level and, if supported by additional evidence, eventually replacing the two-hour test with a ... Our results highlight the potential benefit of
The updates were based on findings from the industry-funded CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trial.
Patients were more likely to choose more intensive care after an annual consultation if they had a high level of education, if they were concerned about illness, if they had set goals for their care, and if they had comorbid conditions.
The findings may reassure prescribers of dipeptidyl peptidase-4 inhibitors that the drug class does not significantly increase the risk of adverse pancreatic outcomes compared with other second-line therapies, study authors said.
The studied risk factors were HbA1c level, LDL cholesterol level, presence of albuminuria, smoking status, and blood pressure.
A study conducted in Australia found that general practitioners with specialization in diabetes care and subspecialist-led clinics reduced HbA1c levels by similar amounts in patients with complex type 2 diabetes.
The findings underscore the urgency of early diagnosis of diabetes and the consequences of failing to achieve near-normal glycemia soon after patients are diagnosed, according to the study authors.